Section Arrow
ACXP.NASDAQ
- Acurx Pharmaceuticals
(Financial Status)
Quotes are at least 15-min delayed:2025/05/25 06:32 EDT
Last
 0.4
+0.0018 (+0.45%)
Day High 
0.4 
Prev. Close
0.3982 
1-M High
0.4532 
Volume 
109.52K 
Bid
0.3908
Ask
0.4
Day Low
0.39 
Open
0.39 
1-M Low
0.34 
Market Cap 
9.35M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.39 
20-SMA 0.39 
50-SMA 0.39 
52-W High 3.325 
52-W Low 0.3 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.70/-0.51
Enterprise Value
9.40M
Balance Sheet
Book Value Per Share
0.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PLRZPolyrizon Ltd0.0034-0.0008-19.05%-- 
IMNNImunon1.16+0.7445+179.18%-- 
NCNANuCana plc0.038-0.0014-3.55%-- 
RXRXRecursion Pharmaceuticals4.08-0.065-1.57%-- 
KLTOKlotho Neurosciences Inc0.1923+0.0033+1.75%-- 
Quotes are at least 15-min delayed:2025/05/25 06:32 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.